Clinical trialObsNot yet recruiting
The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma
The Influence of Secretin Stimulated Pancreatic Secretion on Circulating Tumor DNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Obs
- Status
- Not yet recruiting
- Study type
- Observational
- Start
- 9 February 2025
- Expected end
- 1 February 2027
- Enrollment
- 39 participants
- Sites
- 1
- Primary outcomes
- Plasmatic level of circulating tumor DNA
- Sponsor
- Other
- Results posted
- No
- Last update
- 4 February 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 11
- BackgroundLipidomic profiling of human serum enables detection of pancreatic cancer. DOI 10.1038/s41467-021-27765-9↗
- BackgroundBiomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? DOI 10.3748/wjg.v27.i26.4045↗
- BackgroundPancreatic Ductal Adenocarcinoma: Epidemiology and Risk Factors. DOI 10.3390/diagnostics11030562↗
- BackgroundKRAS mutation in pancreatic cancer. DOI 10.1053/j.seminoncol.2021.02.003↗
- BackgroundCurrent State of "Omics" Biomarkers in Pancreatic Cancer. DOI 10.3390/jpm11020127↗
- BackgroundPancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. DOI 10.4251/wjgo.v12.i2.173↗
- BackgroundThe Role of Exosomes in Pancreatic Cancer. DOI 10.3390/ijms20184332↗
- BackgroundKRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer. DOI 10.1101/cshperspect.a031435↗
- BackgroundMutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring. DOI 10.1634/theoncologist.2017-0467↗
- BackgroundPost-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrosp… DOI 10.1016/j.pan.2016.04.007↗
- BackgroundPancreatic cancer. DOI 10.1016/s0140-6736(16)00141-0↗